Kalaris Therapeutics Stock (NASDAQ:KLRS)
Previous Close
$3.92
52W Range
$2.14 - $11.88
50D Avg
$4.55
200D Avg
$6.60
Market Cap
$69.76M
Avg Vol (3M)
$270.89K
Beta
0.19
Div Yield
-
KLRS Company Profile
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.